FibroBiologics (FBLG) News Today $1.75 -0.16 (-8.38%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period Geode Capital Management LLC Acquires 284,047 Shares of FibroBiologics, Inc. (NASDAQ:FBLG)Geode Capital Management LLC grew its holdings in FibroBiologics, Inc. (NASDAQ:FBLG - Free Report) by 90.0% in the 3rd quarter, according to the company in its most recent filing with the SEC. The firm owned 599,760 shares of the company's stock after buying an additional 284,047 shares during theJanuary 9, 2025 | marketbeat.comFibroBiologics Secures $5M Funding for Strategic GrowthDecember 31, 2024 | tipranks.comFibroBiologics files to sell 41.3M shares of common stock for holdersDecember 31, 2024 | markets.businessinsider.comFibroBiologics Closes Second $5 Million Tranche of $25 Million FinancingDecember 30, 2024 | globenewswire.comD. Boral Capital Served as Exclusive Placement Agent to FibroBiologics, Inc. (Nasdaq: FBLG) in connection with its $25.0 Million FinancingDecember 30, 2024 | investing.comD. Boral Capital Served as Exclusive Placement Agent to FibroBiologics, Inc. (Nasdaq: FBLG) in connection with its $25.0 Million FinancingDecember 30, 2024 | globenewswire.comFibroBiologics' (FBLG) "Buy" Rating Reiterated at D. Boral CapitalD. Boral Capital reaffirmed a "buy" rating and issued a $16.00 price target on shares of FibroBiologics in a report on Friday.December 27, 2024 | marketbeat.comFibroBiologics announces $25M financingDecember 23, 2024 | markets.businessinsider.comFibroBiologics Announces $25 Million FinancingDecember 23, 2024 | globenewswire.comFibroBiologics Resolves Commitments Through Share Issuance AgreementDecember 20, 2024 | tipranks.comFibroBiologics, Inc. (NASDAQ:FBLG) Short Interest UpdateFibroBiologics, Inc. (NASDAQ:FBLG - Get Free Report) was the recipient of a significant increase in short interest in the month of November. As of November 30th, there was short interest totalling 2,700,000 shares, an increase of 6.7% from the November 15th total of 2,530,000 shares. Based on an average daily volume of 376,500 shares, the days-to-cover ratio is presently 7.2 days. Currently, 10.2% of the company's shares are sold short.December 17, 2024 | marketbeat.comRodman & Renshaw Initiates Coverage of FibroBiologics (FBLG) with Buy RecommendationDecember 12, 2024 | msn.comFibroBiologics initiated with a Buy at Rodman & RenshawDecember 12, 2024 | markets.businessinsider.comRodman & Renshaw Initiates Coverage on FibroBiologics (NASDAQ:FBLG)Rodman & Renshaw started coverage on shares of FibroBiologics in a research report on Thursday. They set a "buy" rating and a $12.00 price target for the company.December 12, 2024 | marketbeat.comShort Interest in FibroBiologics, Inc. (NASDAQ:FBLG) Increases By 7.2%FibroBiologics, Inc. (NASDAQ:FBLG - Get Free Report) saw a significant growth in short interest in the month of November. As of November 15th, there was short interest totalling 2,530,000 shares, a growth of 7.2% from the October 31st total of 2,360,000 shares. Approximately 9.4% of the company's stock are short sold. Based on an average daily volume of 402,500 shares, the short-interest ratio is currently 6.3 days.December 3, 2024 | marketbeat.comFibroBiologics seeks patent for spleen disorder treatmentNovember 21, 2024 | investing.comFBLG: On Target to Initiate Phase 1/2 Trial in 2025…November 21, 2024 | finance.yahoo.comFibroBiologics files patent application for cell-based therapeuticNovember 19, 2024 | markets.businessinsider.comFibroBiologics Files Patent Application for a Cell-based Therapeutic for the Treatment Of SplenomegalyNovember 19, 2024 | globenewswire.comPromising Developments and Financial Stability Highlight FibroBiologics’ Near-Term OpportunitiesNovember 15, 2024 | markets.businessinsider.comBrokers Set Expectations for FibroBiologics FY2024 EarningsFibroBiologics, Inc. (NASDAQ:FBLG - Free Report) - Investment analysts at HC Wainwright raised their FY2024 EPS estimates for FibroBiologics in a report issued on Wednesday, November 13th. HC Wainwright analyst M. Caufield now forecasts that the company will post earnings per share of ($0.35) forNovember 15, 2024 | marketbeat.comFibroBiologics files patent application on reduction of clots related to IBMIRNovember 15, 2024 | markets.businessinsider.comFibroBiologics Files Patent Application Covering Reduction of Blood Clots Associated with Instant Blood-Mediated Inflammatory Reaction (IBMIR) in Cell-Based TherapeuticsNovember 14, 2024 | globenewswire.comFibroBiologics Reports Q3 2024 Financial ResultsNovember 14, 2024 | tipranks.comHC Wainwright Reiterates "Buy" Rating for FibroBiologics (NASDAQ:FBLG)HC Wainwright reissued a "buy" rating and issued a $12.00 price target on shares of FibroBiologics in a report on Wednesday.November 13, 2024 | marketbeat.comFibrobiologics, Inc.: FibroBiologics Reports Third Quarter 2024 Financial Results and Provides Corporate UpdateNovember 13, 2024 | finanznachrichten.deFibroBiologics Reports Third Quarter 2024 Financial Results and Provides Corporate UpdateNovember 12, 2024 | globenewswire.comBrokers Offer Predictions for FibroBiologics Q3 EarningsFibroBiologics, Inc. (NASDAQ:FBLG - Free Report) - Equities researchers at HC Wainwright issued their Q3 2024 earnings per share (EPS) estimates for shares of FibroBiologics in a research note issued on Wednesday, October 30th. HC Wainwright analyst M. Caufield forecasts that the company will posNovember 1, 2024 | marketbeat.comFibroBiologics initiated with a Buy at H.C. WainwrightOctober 31, 2024 | markets.businessinsider.comHC Wainwright & Co. Initiates Coverage of FibroBiologics (FBLG) with Buy RecommendationOctober 31, 2024 | msn.comFibroBiologics: A Promising Investment in Immune Restoration and Biotech InnovationOctober 31, 2024 | markets.businessinsider.comFibroBiologics CFO Andersen ResignsOctober 30, 2024 | marketwatch.comFibroBiologics (NASDAQ:FBLG) Now Covered by HC WainwrightHC Wainwright started coverage on FibroBiologics in a report on Wednesday. They issued a "buy" rating and a $12.00 price target for the company.October 30, 2024 | marketbeat.comFibrobiologics, Inc.: FibroBiologics Announces Updates for Novel Artificial Thymus Organoid TechnologyOctober 29, 2024 | finanznachrichten.deFibroBiologics Announces Leadership Changes and New AppointmentsOctober 29, 2024 | markets.businessinsider.comFibroBiologics Announces Updates for Novel Artificial Thymus Organoid TechnologyOctober 29, 2024 | globenewswire.comFibroBiologics to Present at the 2024 ThinkEquity Conference and BIO-Europe 2024October 28, 2024 | globenewswire.comFibroBiologics and Charles River Announce Collaboration to Manufacture Fibroblast Cell-based Therapies for Chronic DiseasesOctober 18, 2024 | globenewswire.comFibrobiologics, Inc.: FibroBiologics Issued Patent for Fibroblast Delivery of Tumor Inhibitory Agents by the European Patent OfficeOctober 17, 2024 | finanznachrichten.deFibroBiologics Shares Rise After European Patent for Fibroblast Cancer TreatmentOctober 16, 2024 | marketwatch.comFibroBiologics Issued Patent for Fibroblast Delivery of Tumor Inhibitory Agents by the European Patent OfficeOctober 16, 2024 | globenewswire.comFibroBiologics, Inc. (NASDAQ:FBLG) Sees Significant Growth in Short InterestFibroBiologics, Inc. (NASDAQ:FBLG - Get Free Report) saw a significant growth in short interest in the month of September. As of September 30th, there was short interest totalling 2,250,000 shares, a growth of 21.6% from the September 15th total of 1,850,000 shares. Based on an average daily volume of 420,300 shares, the days-to-cover ratio is presently 5.4 days. Currently, 8.4% of the shares of the company are short sold.October 14, 2024 | marketbeat.comFibroBiologics to Participate in a Fireside Chat at 2024 Maxim Healthcare Virtual SummitOctober 11, 2024 | globenewswire.comFibroBiologics (NASDAQ:FBLG) Stock Quotes, Forecast and News SummaryOctober 4, 2024 | benzinga.comFibroBiologics to Present at 2024 Cell & Gene Meeting on the MesaSeptember 30, 2024 | globenewswire.comBionomics Limited (B1N0.F) Stock Price, News, Quote & History - Yahoo FinanceSeptember 24, 2024 | finance.yahoo.comFIBROBIOLOGICS INC. (SG0.BE)September 19, 2024 | nz.finance.yahoo.comFibroBiologics Engages Southern Star Research as CRO in AustraliaSeptember 19, 2024 | globenewswire.comFibroBiologics, Inc. (NASDAQ:FBLG) Sees Large Growth in Short InterestFibroBiologics, Inc. (NASDAQ:FBLG - Get Free Report) was the recipient of a large growth in short interest during the month of August. As of August 31st, there was short interest totalling 1,500,000 shares, a growth of 33.9% from the August 15th total of 1,120,000 shares. Based on an average trading volume of 418,700 shares, the days-to-cover ratio is presently 3.6 days. Currently, 5.6% of the company's stock are sold short.September 16, 2024 | marketbeat.comFibroBiologics Announces Filing of Patent Application for Generation of Three-dimensional Organoids using Fibroblast Cell-Based TechnologySeptember 12, 2024 | globenewswire.com Get FibroBiologics News Delivered to You Automatically Sign up to receive the latest news and ratings for FBLG and its competitors with MarketBeat's FREE daily newsletter. Email Address FBLG Media Mentions By Week FBLG Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. FBLG News Sentiment▼0.000.44▲Average Medical News Sentiment FBLG News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. FBLG Articles This Week▼02▲FBLG Articles Average Week Get FibroBiologics News Delivered to You Automatically Sign up to receive the latest news and ratings for FBLG and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies NGNE News Today OLMA News Today ATYR News Today RZLT News Today AVIR News Today CMPX News Today CGC News Today ACIU News Today CADL News Today CCCC News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:FBLG) was last updated on 1/20/2025 by MarketBeat.com Staff From Our PartnersLast time you’ll see this priced at $1.00When was the last time you bought something for a buck? I don’t even think you can buy anything at McDonalds f...StocksToTrade | SponsoredKamala’s final humiliation The investments connected to Trump's second term in ways that almost nobody outside his inner circle is aware ...Porter & Company | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredJanuary 29th - the next big trading catalyst to watch Mark your calendar for January 29th. Because on that day, I believe we could see a $2 Trillion shock INTO t...Timothy Sykes | SponsoredStunning Trump Exec Order LeakedMost people have no clue this unassuming facility exists. Yet the minute Donald Trump takes office... ...Banyan Hill Publishing | SponsoredNvidia’s Bold Move: Tackling Tech’s $1 Trillion CrisisTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding FibroBiologics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share FibroBiologics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
